This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 11.41% and 5.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
by Ahan Chakraborty
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $66.76, moving +0.91% from the previous trading session.
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
by Zacks Equity Research
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Gilead Sciences (GILD) closed at $68.07, indicating a -0.84% shift from the previous trading day.
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the most recent trading session, Gilead Sciences (GILD) closed at $69.94, indicating a +0.75% shift from the previous trading day.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $72.09 in the latest trading session, marking a -1.08% move from the prior day.
Gilead Sciences (GILD) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $72.58, moving -0.04% from the previous trading session.
Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences (GILD) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
Gilead Sciences (GILD) reachead $73.41 at the closing of the latest trading day, reflecting a +0.2% change compared to its last close.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $75.94, moving +1.15% from the previous trading session.
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, Gilead Sciences (GILD) closed at $73.66, indicating a +1.42% shift from the previous trading day.